Top

BMC Complementary Medicine and Therapies

Published in:

01-12-2021 | Dyslipidemia | Research article

Hepatoprotective effect of silymarin on fructose induced nonalcoholic fatty liver disease in male albino wistar rats

Authors: Tewodros Mengesha, Natesan Gnanasekaran, Tsegaye Mehare

Published in: BMC Complementary Medicine and Therapies | Issue 1/2021

Abstract

Background

Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease in the Western world, and it’s likely to parallel the increasing prevalence of type 2 diabetes, obesity, and other components of metabolic syndrome. However, optimal treatment for NAFLD has not been established yet. Therefore, this study investigated the hepatoprotective effect of silymarin on fructose-induced nonalcoholic fatty liver disease in rats.

Methods

Thirty male Wistar rats were randomly divided into five groups; normal control group that consumed tap water, silymarin control group that consumed tap water and silymarin (400 mg/kg/day), fructose control group that consumed 20% fructose solution, treatment group that consumed 20% fructose solution and silymarin (200 mg/kg/day), and another treatment group that consumed 20% fructose solution and silymarin (400 mg/kg/day). Hepatic triglyceride, serum lipid profile, lipid peroxidation, antioxidant level, morphological features, and histopathological changes were investigated. The data were analyzed using one-way analysis of variance (ANOVA) followed by Tukey multiple comparison test. Statistical significance was determined at p < 0.05.

Results

This study showed that the fructose control group had a significantly high value in the stage of steatosis grade, hepatic triglyceride, serum triglyceride, total cholesterol, low-density lipoprotein cholesterol, alanine aminotransferase, aspartate aminotransferase, and hepatic malondialdehyde concentration as compared to the normal control. However, significantly low values of reduced glutathione and plasma total antioxidant capacity were found. The altered parameters due to fructose drastic effect were ameliorated by silymarin treatment.

Conclusions

The fructose control group developed dyslipidemia, oxidative stress, and mild steatosis that are the characteristics features of NAFLD. However, silymarin-treated groups showed amelioration in oxidative stress, dyslipidemia, and steatosis.

Lam BP, Younossi ZM. Treatment regimens for non-alcoholic fatty liver disease. Ann Hepatol. 2009;8(S1):51–9.CrossRef

Pettinelli P, Obregón A, Videla L. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease. Nutr Hosp. 2011;26(3):441–50. https://doi.org/10.1590/S0212-16112011000300003.CrossRefPubMed

Longato L. Non-alcoholic fatty liver disease (NAFLD): a tale of fat and sugar? Fibrogenesis Tissue Repair. 2013;6(1):1–5.CrossRef

Qiu L-X, Chen T. Novel insights into the mechanisms whereby isoflavones protect against fatty liver disease. World J Gastroenterol: WJG. 2015;21(4):1099–107. https://doi.org/10.3748/wjg.v21.i4.1099.CrossRefPubMedPubMedCentral

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. https://doi.org/10.1002/hep.28431.CrossRefPubMed

Seneff S, Wainwright G, Mascitelli L. Is the metabolic syndrome caused by a high fructose, and relatively low fat, low cholesterol diet? Arch Med Sci. 2011;7(1):8–20. https://doi.org/10.5114/aoms.2011.20598.CrossRefPubMedPubMedCentral

Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52(5):1836–46. https://doi.org/10.1002/hep.24001.CrossRefPubMed

Bray GA: Energy and fructose from beverages sweetened with sugar or high-fructose corn syrup pose a health risk for some people. In: Oxford University Press; 2013.

Voinovich D, Perissutti B, Grassi M, Passerini N, Bigotto A. Solid state mechanochemical activation of Silybum marianum dry extract with betacyclodextrins: characterization and bioavailability of the coground systems. J Pharm Sci. 2009;98(11):4119–29. https://doi.org/10.1002/jps.21704.CrossRefPubMed

10.

Pradhan S, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res. 2006;124(5):491–504.PubMed

11.

Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytother Res. 2010;24(10):1423–32. https://doi.org/10.1002/ptr.3207.CrossRefPubMed

12.

Hajiaghamohammadi AA, Ziaee A, Oveisi S, Masroor H, et al. Hepat Mon. 2012;12:8.CrossRef

13.

Aller R, Izaola O, Gómez S, Tafur C, Gonzalez G, Berroa E, Mora N, Gonzalez J, De Luis D. Effect of silymarin plus vitamin E in patients with non-alcoholic fatty liver disease. A randomized clinical pilot study. Eur Rev Med Pharmacol Sci. 2015;19(16):3118–24.PubMed

14.

Hajiani E, Jalal Hashemi S. Comparison of therapeutic effects of silymarin and vitamin e in nonalcoholic fatty liver disease: results of an open-labele, prospective, randomized study. Jundishapur J Nat Pharmaceut Products. 2009;4(1):8–14.

15.

Solhi H, Ghahremani R, Kazemifar AM, Yazdi ZH. Silymarin in treatment of non-alcoholic steatohepatitis: a randomized clinical trial. Caspian J Intern Med. 2014;5(1):9–12.PubMedPubMedCentral

16.

Mamikutty N, Thent ZC, Haji Suhaimi F. Fructose-drinking water induced nonalcoholic fatty liver disease and ultrastructural alteration of hepatocyte mitochondria in male Wistar rat. Biomed Res Int. 2015;2015:1–7. https://doi.org/10.1155/2015/895961.CrossRef

17.

OECD O. Guidance document on acute oral toxicity testing. Paris: OECD; 2000.

18.

Radko L, Cybulski W. Application of silymarin in human and animal medicine. J Pre-Clin Clin Res. 2007:1.

19.

Parasuraman S, Raveendran R, Kesavan R. Blood sample collection in small laboratory animals. J Pharmacol Pharmacother. 2010;1(2):87–93. https://doi.org/10.4103/0976-500X.72350.CrossRefPubMedPubMedCentral

20.

Ruehl-Fehlert C, Kittel B, Morawietz G, Deslex P, Keenan C, Mahrt CR, Nolte T, Robinson M, Stuart BP, Deschl U. Revised guides for organ sampling and trimming in rats and mice–part 1: a joint publication of the RITA and NACAD groups. Exp Toxicol Pathol. 2003;55(2–3):91–106. https://doi.org/10.1078/0940-2993-00311.CrossRefPubMed

21.

Folch J, Lees M, Stanley GS. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226(1):497–509. https://doi.org/10.1016/S0021-9258(18)64849-5.CrossRefPubMed

22.

Danno H, Jincho Y, Budiyanto S, Furukawa Y, Kimura S. A simple enzymatic quantitative analysis of triglycerides in tissues. J Nutr Sci Vitaminol. 1992;38(5):517–21. https://doi.org/10.3177/jnsv.38.517.CrossRefPubMed

23.

Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95(2):351–8. https://doi.org/10.1016/0003-2697(79)90738-3.CrossRefPubMed

24.

Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem. 2004;37(4):277–85. https://doi.org/10.1016/j.clinbiochem.2003.11.015.CrossRefPubMed

25.

Gupta R, Sharma M, Lakshmy R, Prabhakaran D, Reddy KS: Improved method of total antioxidant assay. 2009.

26.

Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82(1):70–7. https://doi.org/10.1016/0003-9861(59)90090-6.CrossRefPubMed

27.

Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem. 1968;25(1):192–205. https://doi.org/10.1016/0003-2697(68)90092-4.CrossRefPubMed

28.

Quaresma AB, d'Acampora AJ, Tramonte R, DCd F, Joly FS. Histological study of the liver and biochemistry of the blood of Wistar rats following ligature of right hepatic duct. Acta Cirurgica Brasileira. 2007;22(1):68–78. https://doi.org/10.1590/S0102-86502007000100013.CrossRefPubMed

29.

Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21. https://doi.org/10.1002/hep.20701.CrossRefPubMed

30.

Rodrigues AA, Andrade RS, Vasconcelos DF. Relationship between experimental diet in rats and nonalcoholic hepatic disease: review of literature. Int J Hepatol. 2018:1–8. https://doi.org/10.1155/2018/9023027.

31.

Van Herck MA, Vonghia L, Francque SM. Animal models of nonalcoholic fatty liver disease—a starter’s guide. Nutrients. 2017;9(10):1072. https://doi.org/10.3390/nu9101072.CrossRefPubMedCentral

32.

Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–23. https://doi.org/10.1002/hep.25762.CrossRefPubMed

33.

Kim M, Yang S-G, Kim JM, Lee J-W, Kim YS, Lee JI. Silymarin suppresses hepatic stellate cell activation in a dietary rat model of non-alcoholic steatohepatitis: Αnalysis of isolated hepatic stellate cells. Int J Mol Med. 2012;30(3):473–9. https://doi.org/10.3892/ijmm.2012.1029.CrossRefPubMedPubMedCentral

34.

Prakash P, Singh V, Jain M, Rana M, Khanna V, Barthwal MK, Dikshit M. Silymarin ameliorates fructose induced insulin resistance syndrome by reducing de novo hepatic lipogenesis in the rat. Eur J Pharmacol. 2014;727:15–28. https://doi.org/10.1016/j.ejphar.2014.01.038.CrossRefPubMed

35.

Serviddio G, Bellanti F, Giudetti AM, Gnoni GV, Petrella A, Tamborra R, Romano AD, Rollo T, Vendemiale G, Altomare E. A silybin-phospholipid complex prevents mitochondrial dysfunction in a rodent model of nonalcoholic steatohepatitis. J Pharmacol Exp Ther. 2010;332(3):922–32. https://doi.org/10.1124/jpet.109.161612.CrossRefPubMed

36.

Tsai J, Liu J-Y, Wu T, Ho P, Huang C-Y, Shyu J, Hsieh Y, Tsai C, Liu Y. Effects of silymarin on the resolution of liver fibrosis induced by carbon tetrachloride in rats. J Viral Hepat. 2008;15(7):508–14. https://doi.org/10.1111/j.1365-2893.2008.00971.x.CrossRefPubMed

37.

Wu J-P, Tsai C-C, Yeh Y-L, Lin Y-M, Lin C-C, Day CH, Shen C-Y, Padma VV, Pan L-F, Huang C-Y. Silymarin accelerates liver regeneration after partial hepatectomy. Evid Based Complement Alternat Med. 2015;2015:1–14. https://doi.org/10.1155/2015/603529.CrossRef

38.

Yao J, Zhi M, Gao X, Hu P, Li C, Yang X. Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver. Braz J Med Biol Res. 2013;46(3):270–7. https://doi.org/10.1590/1414-431X20122551.CrossRefPubMedPubMedCentral

39.

Abdulla MH, Sattar MA, Abdullah NA, Khan MAH, Swarup KRA, Johns EJ. The contribution of α 1B-adrenoceptor subtype in the renal vasculature of fructose-fed Sprague–Dawley rats. Eur J Nutr. 2011;50(4):251–60. https://doi.org/10.1007/s00394-010-0133-8.CrossRefPubMed

40.

Wang J, Gao H, Ke D, Zuo G, Yang Y, Yamahara J, Li Y. Improvement of liquid fructose-induced adipose tissue insulin resistance by ginger treatment in rats is associated with suppression of adipose macrophage-related proinflammatory cytokines. Evid Based Complement Alternat Med. 2013;2013:1–12. https://doi.org/10.1155/2013/590376.

41.

Cardinali DP, Bernasconi PAS, Reynoso R, Toso CFR, Scacchi P. Melatonin may curtail the metabolic syndrome: studies on initial and fully established fructose-induced metabolic syndrome in rats. Int J Mol Sci. 2013;14(2):2502–14. https://doi.org/10.3390/ijms14022502.CrossRefPubMedPubMedCentral

42.

Ni X, Wang H. Silymarin attenuated hepatic steatosis through regulation of lipid metabolism and oxidative stress in a mouse model of nonalcoholic fatty liver disease (NAFLD). Am J Transl Res. 2016;8(2):1073–81.PubMedPubMedCentral

43.

Bergheim I, Weber S, Vos M, Krämer S, Volynets V, Kaserouni S, McClain CJ, Bischoff SC. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol. 2008;48(6):983–92. https://doi.org/10.1016/j.jhep.2008.01.035.CrossRefPubMed

44.

Jürgens H, Haass W, Castaneda TR, Schürmann A, Koebnick C, Dombrowski F, Otto B, Nawrocki AR, Scherer PE, Spranger J. Consuming fructose-sweetened beverages increases body adiposity in mice. Obes Res. 2005;13(7):1146–56. https://doi.org/10.1038/oby.2005.136.CrossRefPubMed

45.

Guo Y, Wang S, Wang Y, Zhu T. Silymarin improved diet-induced liver damage and insulin resistance by decreasing inflammation in mice. Pharm Biol. 2016;54(12):2995–3000. https://doi.org/10.1080/13880209.2016.1199042.CrossRefPubMed

46.

Sayin FK, Buyukbas S, Basarali MK, Alp H, Toy H, Ugurcu V. Effects of Silybum marianum extract on high-fat diet induced metabolic disorders in rats. Polish J Food Nutr Sci. 2016;66(1):43–50. https://doi.org/10.1515/pjfns-2015-0014.CrossRef

47.

Poudyal H, Panchal SK, Ward LC, Waanders J, Brown L. Chronic high-carbohydrate, high-fat feeding in rats induces reversible metabolic, cardiovascular, and liver changes. Am J Physiol-Endocrinol Metab. 2012;302(12):E1472–82. https://doi.org/10.1152/ajpendo.00102.2012.CrossRefPubMed

48.

Haddad Y, Vallerand D, Brault A, Haddad PS. Antioxidant and hepatoprotective effects of silibinin in a rat model of nonalcoholic steatohepatitis. Evid Based Complement Alternat Med. 2011;2011:1–10. https://doi.org/10.1093/ecam/nep164.CrossRef

49.

Liu S-H, Cai F-Y, Chiang M-T. Long-term feeding of chitosan ameliorates glucose and lipid metabolism in a high-fructose-diet-impaired rat model of glucose tolerance. Marine Drugs. 2015;13(12):7302–13. https://doi.org/10.3390/md13127067.CrossRefPubMedPubMedCentral

50.

Senaphan K, Kukongviriyapan U, Sangartit W, Pakdeechote P, Pannangpetch P, Prachaney P, Greenwald SE, Kukongviriyapan V. Ferulic acid alleviates changes in a rat model of metabolic syndrome induced by high-carbohydrate, high-fat diet. Nutrients. 2015;7(8):6446–64. https://doi.org/10.3390/nu7085283.CrossRefPubMedPubMedCentral

51.

Marin V, Gazzin S, Gambaro SE, Dal Ben M, Calligaris S, Anese M, Raseni A, Avellini C, Giraudi PJ, Tiribelli C. Effects of oral administration of silymarin in a juvenile murine model of non-alcoholic steatohepatitis. Nutrients. 2017;9(9):1006. https://doi.org/10.3390/nu9091006.CrossRefPubMedCentral

52.

Sun R, Xu D, Wei Q, Zhang B, Aa J, Wang G, Xie Y. Silybin ameliorates hepatic lipid accumulation and modulates global metabolism in an NAFLD mouse model. Biomed Pharmacother. 2020;123:109721. https://doi.org/10.1016/j.biopha.2019.109721.CrossRefPubMed

53.

Roth CL, Elfers CT, Figlewicz DP, Melhorn SJ, Morton GJ, Hoofnagle A, Yeh MM, Nelson JE, Kowdley KV. Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and toll-like receptor activation. Hepatology. 2012;55(4):1103–11. https://doi.org/10.1002/hep.24737.CrossRefPubMed

54.

Aragno M, Tomasinelli CE, Vercellinatto I, Catalano MG, Collino M, Fantozzi R, Danni O, Boccuzzi G. SREBP-1c in nonalcoholic fatty liver disease induced by Western-type high-fat diet plus fructose in rats. Free Radic Biol Med. 2009;47(7):1067–74. https://doi.org/10.1016/j.freeradbiomed.2009.07.016.CrossRefPubMed

55.

Panchal SK, Wong W-Y, Kauter K, Ward LC, Brown L. Caffeine attenuates metabolic syndrome in diet-induced obese rats. Nutrition. 2012;28(10):1055–62. https://doi.org/10.1016/j.nut.2012.02.013.CrossRefPubMed

56.

Sabiu S, Sunmonu TO, Ajani EO, Ajiboye TO. Combined administration of silymarin and vitamin C stalls acetaminophen-mediated hepatic oxidative insults in Wistar rats. Rev Bras. 2015;25(1):29–34. https://doi.org/10.1016/j.bjp.2014.11.012.CrossRef

57.

Armutcu F, Coskun Ö, Gürel A, Kanter M, Can M, Ucar F, Unalacak M. Thymosin alpha 1 attenuates lipid peroxidation and improves fructose-induced steatohepatitis in rats. Clin Biochem. 2005;38(6):540–7. https://doi.org/10.1016/j.clinbiochem.2005.01.013.CrossRefPubMed

58.

Du D, Shi Y-H, Le G-W. Oxidative stress induced by high-glucose diet in liver of C57BL/6J mice and its underlying mechanism. Mol Biol Rep. 2010;37(8):3833–9. https://doi.org/10.1007/s11033-010-0039-9.CrossRefPubMed

59.

Takeuchi M, Iwaki M, Takino J-I, Shirai H, Kawakami M, Bucala R, Yamagishi S-I. Immunological detection of fructose-derived advanced glycation end-products. Lab Investig. 2010;90(7):1117–27. https://doi.org/10.1038/labinvest.2010.62.CrossRefPubMed

60.

Grasselli E, Baldini F, Vecchione G, Oliveira PJ, Sardão VA, Voci A, Portincasa P, Vergani L. Excess fructose and fatty acids trigger a model of non-alcoholic fatty liver disease progression in vitro: protective effect of the flavonoid silybin. Int J Mol Med. 2019;44(2):705–12. https://doi.org/10.3892/ijmm.2019.4234.CrossRefPubMed

61.

Kheiripour N, Karimi J, Khodadadi I, Tavilani H, Goodarzi MT, Hashemnia M. Hepatoprotective effects of silymarin on liver injury via irisin upregulation and oxidative stress reduction in rats with type 2 diabetes. Iran J Med Sci. 2019;44(2):108–17.PubMed

62.

Shaker E, Mahmoud H, Mnaa S. Silymarin, the antioxidant component and Silybum marianum extracts prevent liver damage. Food Chem Toxicol. 2010;48(3):803–6. https://doi.org/10.1016/j.fct.2009.12.011.CrossRefPubMed

63.

Yao J, Zhi M, Minhu C. Effect of silybin on high-fat-induced fatty liver in rats. Braz J Med Biol Res. 2011;44(7):652–9. https://doi.org/10.1590/s0100-879x2011007500083.CrossRefPubMed

64.

Alisi A, Da Sacco L, Bruscalupi G, Piemonte F, Panera N, De Vito R, Leoni S, Bottazzo GF, Masotti A, Nobili V. Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. Lab Investig. 2011;91(2):283–93. https://doi.org/10.1038/labinvest.2010.166.CrossRefPubMed

Title: Hepatoprotective effect of silymarin on fructose induced nonalcoholic fatty liver disease in male albino wistar rats
Authors: Tewodros Mengesha
Natesan Gnanasekaran
Tsegaye Mehare
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Dyslipidemia
Fatty Liver
Published in: BMC Complementary Medicine and Therapies / Issue 1/2021
Electronic ISSN: 2662-7671
DOI: https://doi.org/10.1186/s12906-021-03275-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Hepatoprotective effect of silymarin on fructose induced nonalcoholic fatty liver disease in male albino wistar rats

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Community education and health promotion activities of naturopathic practitioners: results of an international cross-sectional survey

Investigation of the idiosyncratic hepatotoxicity of Polygonum multiflorum Thunb. through metabolomics using GC-MS

Antidiarrheal, antimicrobial and antioxidant potentials of methanol extract of Colocasia gigantea Hook. f. leaves: evidenced from in vivo and in vitro studies along with computer-aided approaches

Indole alkaloids inhibit zika and chikungunya virus infection in different cell lines

Curcumin protects radiation-induced liver damage in rats through the NF-κB signaling pathway

Effect of supercritical carbon dioxide fluid extract from Chrysanthemum indicum Linné on bleomycin-induced pulmonary fibrosis